KRTL HOLDING GROUP INC. REPORTS THIRD QUARTER 2025 RESULTS (UNAUDITED) AND FILES PCAOB-AUDITED 2024 AND 2023 FINANCIAL STATEMENTS

Rhea-AI Summary

KRTL Holding Group (OTC: KRTL) reported third-quarter 2025 results and completed a PCAOB audit of its 2024 and 2023 consolidated financial statements with no changes to previously reported unaudited amounts.

The company closed its acquisition of Industria Químico Farmacéutica Sigma Corp. S.R.L. on Sept 2, 2025; Sigma contributed $1,752,656 of revenue in the 28 days included in Q3, helping drive total Q3 revenue of $1,815,781. Sigma generated approximately $19.7M revenue and a 57% gross margin for the six months ended Sept 30, 2025, implying an annualized run rate near $40M.

Consolidated totals as of Sept 30, 2025: $23.8M total assets and $8.7M shareholders’ equity. Management said PCAOB-audited financials position the company to evaluate an uplisting, subject to listing requirements.

Positive

• PCAOB audit completed for 2024 and 2023 with no changes
• Sigma contributed $1,752,656 to Q3 2025 revenue (28 days)
• Sigma six-month revenue $19.7M with 57% gross margin
• Consolidated $23.8M total assets and $8.7M shareholders’ equity

Negative

• Sigma operations accounted for ~96.5% of Q3 revenue, indicating concentration
• Sigma manufacturing plant operating at ~40% capacity (underutilization)

Lakewood, CO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) (the “Company”) reported financial results for the three and nine months ended September 30, 2025, and announced the completion of a PCAOB audit of its consolidated financial statements for the years ended December 31, 2024, and 2023.

Cesar Herrera, the Company’s Chief Executive Officer, said: “We are pleased to announce that we now have PCAOB-audited financial statements for our previous two fiscal years and that there were no changes to the previously reported unaudited amounts. Additionally, we are very excited to report our three- and nine-month results for the period ended September 30, 2025, which include 28 days of operations from our newly acquired subsidiary, Industria Químico Farmacéutica Sigma Corp. S.R.L. (‘Sigma’), following its acquisition on September 2, 2025.”

Revenue from the 28 days of operations of the Sigma subsidiary amounted to $1,752,656 in the three months ended September 30, 2025.  Total revenues for the Company for the three months ended September 30, 2025, amounted to $1,815,781.

Management believes that the Sigma acquisition provides a scalable revenue base, particularly as the Company prepares to expand distribution of pharmaceuticals and nutraceuticals across international markets, including a planned entry into the United States. On a standalone basis, for the six months ended September 30, 2025, Sigma generated revenue of approximately $19.7 million and a gross margin of 57%, implying an annualized revenue run rate of approximately $40 million based solely on that period’s results. Based on management’s internal capacity assessments and given that Sigma’s manufacturing plant is currently operating at approximately 40% of its capacity, management believes that the existing facility could support up to approximately $100 million in annual revenue without a commensurate increase in fixed manufacturing costs.

“On a consolidated basis, as of September 30, 2025, we now have approximately $23.8 million in total assets and $8.7 million in total shareholders’ equity,” continued Herrera. “The completion of our PCAOB audit is also an important step in positioning the Company to pursue an uplisting to a higher-tier trading venue, so that a broader universe of potential investors can evaluate our business.”

With PCAOB-audited financial statements now in place, the Company intends to evaluate and pursue an uplisting to a more senior marketplace or exchange, subject to satisfying applicable listing requirements and market conditions. Management believes that an uplisting could enhance the Company’s visibility, improve trading liquidity, and make KRTL more accessible to institutional and other investors who are restricted from investing in lower-tier markets.

The Company has uploaded its Quarterly Report for the period ended September 30, 2025, together with its PCAOB-audited financial statements for the years ended December 31, 2024, and 2023, to OTC Markets. Investors are encouraged to review those filings for a complete discussion of the Company’s financial condition and operating results.

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.

www.krtlholding.com
info@krtlholding.com

IR-855-KRTL-HLD Option 2
IR Email: KRTl@agglobalpartners.com

www.krtlbiotech.com
info@krtlbiotech.com

www.krtl-icc.com
info@krtl-icc.com

FAQ

How much revenue did KRTL (OTC: KRTL) report for Q3 2025 and how much came from Sigma?

KRTL reported $1,815,781 for Q3 2025; $1,752,656 of that came from Sigma's 28 days of operations.

What were Sigma's results for the six months ended Sept 30, 2025 reported by KRTL (KRTL)?

Sigma generated approximately $19.7M in six-month revenue with a 57% gross margin.

Did KRTL complete a PCAOB audit and will it pursue an uplisting (KRTL)?

Yes; KRTL completed PCAOB-audited financials for 2024 and 2023 with no changes and said it will evaluate an uplisting subject to listing requirements.

What are KRTL's consolidated assets and shareholders’ equity as of Sept 30, 2025 (KRTL)?

KRTL reported consolidated total assets of $23.8M and shareholders’ equity of $8.7M as of Sept 30, 2025.

What does Sigma's operating capacity imply for KRTL's potential revenue (KRTL)?

Management reported Sigma's plant is operating at ~40% capacity and could support up to ~$100M in annual revenue without a commensurate increase in fixed manufacturing costs.